Phathom Pharmaceuticals (PHAT) Cost of Revenue (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Cost of Revenue for 4 consecutive years, with $15.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cost of Revenue rose 199.64% year-over-year to $15.1 million; the TTM figure through Jun 2026 stood at $40.9 million (up 174.09% YoY), while the FY2025 annual figure was $22.6 million, up 183.44% from the prior year.
• Cost of Revenue improved to $15.1 million in Q2 2026 per PHAT's latest filing, from $12.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $15.1 million in Q2 2026 and bottomed at $167000.0 in Q4 2023.
• Historically, Cost of Revenue has averaged $5.3 million across 4 years, with a median of $3.8 million in 2024.
• Annual changes were most pronounced in 2024 — Cost of Revenue jumped 2184.43% — and 2025, when it jumped 100.47%.
• Phathom Pharmaceuticals' Cost of Revenue stood at $167000.0 in 2023, then surged by 2184.43% to $3.8 million in 2024, then jumped by 100.47% to $7.6 million in 2025, then jumped by 97.38% to $15.1 million in 2026.
• Business Quant data shows PHAT's Cost of Revenue at $15.1 million in Q2 2026, $12.0 million in Q1 2026, and $7.6 million in Q4 2025.